FDA 510(k) Cleared vs Investigational Drug Tests: A Procurement Risk Guide

FDA 510(k) Cleared vs Investigational Drug Tests: A Procurement Risk Guide

Quick answer: An FDA 510(k) Cleared drug test has been reviewed by the Food and Drug Administration and determined substantially equivalent to a legally marketed predicate device for a specific intended use, supporting clinical decisions in workplace and patient care settings; an Investigational device is authorized only for clinical investigation under an Investigational Device Exemption; and a Research Use Only device is restricted to non-clinical research and is not intended to support clinical or workplace decision-making — using an RUO or IDE device for routine clinical or workplace screening creates regulatory, liability, and reimbursement exposure that procurement officers must specifically address.

>

Key data points:

- The FDA receives approximately 3,500 to 4,500 new 510(k) submissions per year across all medical device categories, with In Vitro Diagnostics representing a substantial subset (FDA CDRH annual report data).

- The 510(k) substantial equivalence framework, codified at 21 USC 360c(f)(1), has cleared more than 175,000 devices since its inception in 1976 (FDA cumulative clearance data).

- FDA Office of In Vitro Diagnostics enforcement actions involving Research Use Only labeling misuse have ranged from warning letters to product seizure across multiple manufacturers in recent years (FDA enforcement database).

- Approximately 21 CFR 809.10(c) prescribes the specific intended use and labeling requirements that distinguish RUO and IUO products from cleared in vitro diagnostics (Code of Federal Regulations).

Last updated: 2026-06-02 · ~16 min read · Sources: 21 CFR Parts 807 and 809; 21 USC 360c; FDA CDRH guidance documents; FDA enforcement actions database; CLIA program requirements

---

A drug test is a regulated medical device, and the regulatory status under which it is marketed dictates the clinical, legal, and reimbursement consequences of using it. Procurement officers at hospitals, reference laboratories, federal agencies, and large employers who treat drug testing devices as undifferentiated commodities expose their institutions to a tier of risk that is easily avoided through specification discipline. The distinction between FDA 510(k) Cleared, Investigational, and Research Use Only is not a marketing nuance — it is a substantive regulatory boundary established by statute, codified in the Code of Federal Regulations, and enforced by the FDA's Office of Compliance.

This guide is written for hospital quality assurance directors, regulatory affairs officers, clinical procurement leads, and reference laboratory directors who own the buying decision for drug testing devices and must defend that decision to compliance officers, payers, and litigation counsel. American Screening Corp. (ASC) markets FDA 510(k) Cleared drug testing devices under specific intended use statements, with CLIA-Waived classification for point-of-care applications, manufactured under ISO 13485 quality systems.

---

The statutory framework: how the FDA classifies in vitro diagnostics

The Food, Drug, and Cosmetic Act, as amended by the Medical Device Amendments of 1976 and subsequent statutes, divides medical devices into three classes based on the regulatory controls necessary to ensure safety and effectiveness. Class I devices are subject to general controls, Class II devices to general controls plus special controls (commonly including 510(k) premarket notification), and Class III devices to general controls plus premarket approval. Most in vitro diagnostic drug screening devices fall within Class II under 21 CFR Part 866 Subpart E.

The 510(k) premarket notification process, codified at 21 USC 360c and implemented at 21 CFR Part 807 Subpart E, requires manufacturers to demonstrate that a device is substantially equivalent to a legally marketed predicate device. Substantial equivalence means the device has the same intended use as the predicate and either the same technological characteristics or different characteristics that do not raise different questions of safety and effectiveness. When the FDA agrees the device is substantially equivalent, the agency issues a 510(k) clearance letter, and the device may be marketed for its cleared intended use.

The clearance is specific to the intended use stated in the submission. A device cleared for in vitro diagnostic use as a workplace drug screen is cleared for that purpose; using the same physical device for an intended use outside the cleared statement — such as for clinical patient management when the clearance is for workplace screening — exposes the user to off-label use considerations and potentially to investigator or user-manufacturer status under FDA regulations. Procurement officers should verify not only that a device is 510(k) Cleared but that the clearance covers the intended use the procuring institution will actually make of it.

The two principal alternatives to 510(k) clearance are the Investigational Device Exemption and the Research Use Only labeling pathway. An IDE under 21 CFR Part 812 authorizes the use of an investigational device in a clinical investigation to gather safety and effectiveness data. An RUO device under 21 CFR 809.10(c)(2)(i) is restricted by labeling to non-clinical research and is not intended to support clinical decision-making. These pathways serve legitimate purposes for genuine research and investigation but are not appropriate for routine clinical or workplace screening procurement.

Comparison: 510(k) Cleared vs Investigational vs Research Use Only

The three pathways have meaningfully different regulatory status, intended use, and procurement implications. Procurement specifications that confuse them produce contracts that expose the institution to enforcement, liability, and reimbursement risk.

Regulatory dimension	FDA 510(k) Cleared	Investigational (IDE)	Research Use Only (RUO)
Statutory authority	21 USC 360(k); 21 CFR Part 807	21 USC 360j(g); 21 CFR Part 812	21 CFR 809.10(c)(2)(i)
Intended use	Stated in 510(k) submission and clearance letter	Limited to investigational protocol	Non-clinical research only
Required labeling	Per cleared submission and 21 CFR 809.10	"CAUTION—Investigational device. Limited by Federal law to investigational use."	"For Research Use Only. Not for use in diagnostic procedures."
Permitted clinical use	Yes, within cleared intended use	Only under IRB-approved protocol	No
Permitted workplace screening	Yes, if cleared for that use	No	No
Reimbursement	Generally eligible	Limited; investigational status often excludes coverage	Not eligible
Liability exposure if misused	Off-label use considerations	Significant; unauthorized clinical use violates IDE	Significant; clinical use violates RUO labeling
Procurement risk	Low when intended use matches	High; requires IRB and investigational infrastructure	High; not suitable for routine procurement
CLIA-Waived status available	Yes, when reviewed and granted	No	No
Quality system requirement	21 CFR Part 820 (QSR)	21 CFR Part 812 + applicable QSR	Generally not subject to QSR clinical performance

The procurement implication of this matrix is decisive. For workplace drug screening, clinical patient management, hospital admission protocols, and any application where the result will support a clinical or employment decision, the procurement specification must require 510(k) clearance for the relevant intended use. RUO and IUO devices are not acceptable substitutes regardless of price. IDE devices are not appropriate outside of an IRB-approved investigational protocol with the infrastructure to support FDA-compliant clinical investigation.

How RUO mislabeling enforcement actually plays out

FDA enforcement against improper marketing or use of Research Use Only products has produced a substantial record of warning letters, untitled letters, and consent decrees over the past two decades. The pattern is consistent. A manufacturer markets an RUO-labeled product with marketing materials, sales practices, or distribution patterns that indicate the manufacturer is promoting the product for clinical use. Alternatively, a clinical laboratory or healthcare provider uses an RUO product for patient care and the use surfaces during inspection. The FDA responds with enforcement action against the manufacturer, the user, or both.

The Office of In Vitro Diagnostics and Radiological Health has been explicit in guidance that the RUO designation is determined by both labeling and totality of circumstances, including marketing claims, sales channels, and known customer base. A manufacturer that ships an RUO-labeled product to clinical laboratories with knowledge that the laboratory will use it for clinical purposes is exposed to enforcement notwithstanding the RUO label on the box. Procurement officers who purchase RUO products for clinical use participate in the regulatory exposure.

The downstream consequences include product seizure, recall, civil money penalties, and in serious cases criminal prosecution. For the procuring institution, the consequences also include reimbursement disallowance, failed inspection findings (CLIA, CAP, Joint Commission), and potential liability exposure if a patient or employee challenges a decision made on the basis of an RUO-derived result.

The procurement specification protection is straightforward. Solicitations and contracts should require, in writing, that all in vitro diagnostic devices supplied under the contract carry FDA 510(k) clearance for the intended use the procuring institution will make of them, and should require the vendor to provide the 510(k) clearance number and clearance letter on demand. Devices labeled RUO or IUO should be expressly excluded from contract scope. ASC's product line is structured around FDA 510(k) Cleared devices specifically to support this procurement specification.

Intended use: the most important phrase in the 510(k) clearance

The intended use statement is the operative legal language in a 510(k) clearance. It is drafted by the manufacturer, reviewed by the FDA, and recited in the clearance letter. It defines the scope of the clearance, and using the device outside that scope constitutes off-label use that may carry significant regulatory and liability implications depending on the application.

For drug testing devices, common intended use statements address the specimen type (urine, oral fluid, hair), the analyte panel, the cutoff concentrations, the screening or confirmatory nature of the result, the testing environment (point of collection, laboratory), and the user qualification (lay user, healthcare professional). A device cleared for urine drug screening at SAMHSA cutoffs in a CLIA-Waived environment is not automatically cleared for oral fluid testing or for cutoffs other than those evaluated.

Procurement officers should review the actual 510(k) clearance letter — not the marketing brochure — for each device specified in a contract. The clearance letter recites the intended use as cleared and identifies the predicate device. The K-number indexes to the FDA's public 510(k) database where the clearance documentation can be verified. ASC publishes 510(k) documentation through its certificate of analysis program and makes clearance letters available on request for procurement diligence.

For specialized applications — pediatric testing, hair testing, oral fluid in specific environments, novel analytes — procurement should verify that the proposed device's clearance specifically addresses the application. Where it does not, the procurement should either select a different device whose clearance does address the application or accept that the application is an off-label use with the associated risk profile.

CLIA classification and how it intersects with FDA clearance

The Clinical Laboratory Improvement Amendments of 1988 establish federal standards for laboratory testing performed on human specimens. CLIA classifies tests as waived, moderate complexity, or high complexity based on a set of FDA-administered criteria. The classification determines the regulatory requirements that apply to the testing site.

For drug testing, the CLIA classification is determined as part of the FDA's review of the 510(k) submission or by a subsequent CLIA categorization decision. CLIA-Waived devices may be used at sites holding a Certificate of Waiver, which is the simplest CLIA registration. Moderate and high complexity tests require Certificates of Compliance or Accreditation and impose proficiency testing, quality control, and personnel qualification requirements.

The intersection of FDA clearance and CLIA classification matters for procurement because the same physical device may not be available in all classifications. A device cleared and CLIA-Waived for use with one specimen type may be moderate complexity for use with another. A device cleared at one cutoff may be classified differently if used at different cutoffs through laboratory-developed modifications.

For point-of-collection testing in employer programs, treatment center clinical settings, and similar non-laboratory environments, CLIA-Waived classification is the procurement target. For hospital laboratory drug screening, moderate complexity classification is common. Procurement specifications should align the CLIA classification with the testing site's CLIA certification and capability. ASC supplies CLIA-Waived FDA 510(k) Cleared cups specifically for point-of-collection settings and supplies laboratory-grade devices for moderate complexity environments.

The predicate device chain and what it tells procurement officers

A 510(k) clearance is granted based on substantial equivalence to a legally marketed predicate device. The predicate may itself have been cleared based on equivalence to an earlier predicate, and that chain may extend back through multiple devices to a foundational predicate cleared shortly after the Medical Device Amendments of 1976.

Long predicate chains have been the subject of regulatory and academic critique. The concern is that incremental modifications across a long chain may produce a current device that differs substantially from the foundational predicate without ever having undergone full premarket review of the differences. The FDA has responded with the "Refuse to Accept" policy, enhanced substantial equivalence reviews, and in some cases reclassification of device types to require alternative pathways.

For procurement officers, the practical implication is that the K-number alone does not tell the full story. Diligence for high-stakes applications may include reviewing the predicate chain, identifying the testing performed in support of the most recent clearance, and verifying that the device's actual performance in the intended use environment is well-characterized. ASC supplies clinical performance data, predicate device information, and clearance documentation on request for procurement diligence purposes.

Liability and litigation considerations

Drug testing decisions are litigated frequently. Employment terminations based on drug test results produce wrongful termination and discrimination claims. Custody and visitation decisions in family law turn on drug test results. Hospital admission and treatment decisions based on toxicology may produce malpractice claims. The regulatory status of the device used to produce the result becomes a factor in each of these proceedings.

A result produced by an FDA 510(k) Cleared device used within its cleared intended use enters litigation with substantial regulatory support. The clearance establishes that the FDA has reviewed the device, found it substantially equivalent to a legally marketed predicate, and authorized its marketing for the intended use. Plaintiff's counsel must build any challenge against that baseline.

A result produced by an RUO-labeled device used clinically enters litigation with a built-in liability exposure. The label explicitly disclaims clinical use. The institution's decision to use the device for clinical purposes is potentially negligent on its face, and defense counsel must justify the procurement decision against a labeling restriction that the institution disregarded.

A result produced by an IDE device used outside the investigational protocol enters litigation with potential federal regulatory exposure layered on top of the underlying liability claim. The IDE imposes specific conditions on use, and use outside those conditions may constitute violation of the investigational authorization.

Procurement officers who specify 510(k) Cleared devices for clinical and workplace applications eliminate this category of exposure at the procurement stage. The specification cost is minimal — 510(k) Cleared devices are widely available at competitive pricing — and the liability protection is significant.

Statistical and regulatory context for the procurement file

Procurement files for in vitro diagnostic drug testing benefit from documenting the statistical and regulatory context for the specifications chosen.

"The FDA receives approximately 3,500 to 4,500 new 510(k) submissions per year across all medical device categories, with In Vitro Diagnostics representing a substantial subset" (FDA CDRH annual report data). The 510(k) program is mature, high-volume, and well-understood by the regulated industry and by procurement professionals.

"The 510(k) substantial equivalence framework has cleared more than 175,000 devices since its inception in 1976" (FDA cumulative clearance data). The framework is the dominant regulatory pathway for medical devices in the United States and is the appropriate baseline expectation for any commercial in vitro diagnostic procurement.

"FDA Office of In Vitro Diagnostics enforcement actions involving Research Use Only labeling misuse have ranged from warning letters to product seizure across multiple manufacturers in recent years" (FDA enforcement database). RUO-labeling exposure is not theoretical; it has produced material enforcement against manufacturers and users of mislabeled or misused devices.

"21 CFR 809.10(c) prescribes the specific intended use and labeling requirements that distinguish RUO and IUO products from cleared in vitro diagnostics" (Code of Federal Regulations). The distinction is codified in regulation rather than left to interpretation, and the labeling requirements are explicit.

ASC's regulatory affairs positioning includes FDA 510(k) Cleared drug testing devices across a multi-panel product line, CLIA-Waived classification for point-of-collection products, ISO 13485 quality management system certification, lot-coded devices with QR-linked certificates of analysis, Shreveport, Louisiana same-day dispatch before 2 p.m. Central, NET-30 terms for qualified institutional purchasers, and volume pricing at 10, 50, 100, 500, and 1,000-plus tiers. The Hospitals industry program and the CLIA-Waived FDA cleared cups collection consolidate the offering for clinical procurement.

Practical procurement checklist

The following items should appear in every in vitro diagnostic drug testing procurement specification.

1. Require FDA 510(k) clearance for the relevant intended use; identify K-number in bid response.
2. Require the clearance letter or FDA database link to be available on request.
3. Require the bidder to confirm in writing that the intended use cleared by the FDA matches the procuring institution's actual use.
4. Expressly exclude Research Use Only and Investigational devices from contract scope.
5. Specify the required CLIA classification aligned with the testing site's CLIA certification.
6. Require ISO 13485 or equivalent quality management system certification.
7. Require lot-coded devices with QR-linked certificates of analysis for traceability.
8. Require labeling compliance with 21 CFR 809.10 for in vitro diagnostic products.
9. Specify expectations for clinical performance data on request.
10. Specify product recall notification procedures.
11. Specify product change notification procedures for any change that affects clearance scope.
12. Specify indemnification for regulatory non-compliance attributable to the vendor.

Frequently asked questions

What does FDA 510(k) clearance actually mean?

FDA 510(k) clearance is a determination by the Food and Drug Administration that a medical device is substantially equivalent to a legally marketed predicate device for a specific intended use. Substantial equivalence means the device has the same intended use as the predicate and either the same technological characteristics or different characteristics that do not raise different questions of safety and effectiveness. Clearance authorizes the manufacturer to market the device for the cleared intended use; it is not equivalent to FDA "approval," which is a separate premarket approval pathway used for higher-risk devices.

Can a Research Use Only device be used for clinical drug testing?

No. Research Use Only labeling under 21 CFR 809.10(c)(2)(i) restricts the product to non-clinical research. Using an RUO product for clinical drug testing or workplace screening violates the labeling restriction, exposes the institution to FDA enforcement risk, may disqualify the test for reimbursement, and undermines the result's defensibility in litigation. Procurement specifications should expressly exclude RUO products for any clinical or workplace application.

What is the difference between FDA 510(k) Cleared and FDA Approved?

510(k) Cleared and FDA Approved are distinct regulatory determinations. 510(k) Clearance is the substantial equivalence pathway used for most Class II devices, including most in vitro diagnostic drug screening devices. FDA Approval is the premarket approval pathway used for Class III devices that require demonstration of safety and effectiveness independent of any predicate. The terms are sometimes used interchangeably in marketing but are not synonymous. For drug screening devices, 510(k) Cleared is typically the correct and sufficient regulatory status.

Why does intended use matter so much for procurement?

The 510(k) clearance is specific to the intended use stated in the submission and recited in the clearance letter. Using a device outside its cleared intended use is off-label use, which carries regulatory and liability implications. Procurement specifications should require the bidder to confirm that the cleared intended use matches the procuring institution's actual use, and should request the clearance letter for verification. The intended use statement is the operative legal language; marketing brochures are not a substitute.

What is CLIA-Waived and how does it relate to FDA clearance?

CLIA-Waived is a classification under the Clinical Laboratory Improvement Amendments that applies to tests determined to be simple and to have a low risk of erroneous results. CLIA classification is administered by the FDA in coordination with CMS and is typically determined as part of the 510(k) review. A CLIA-Waived FDA 510(k) Cleared device may be used at sites holding a CLIA Certificate of Waiver, which is the simplest CLIA registration. The combination supports point-of-collection testing in employer, treatment center, and similar non-laboratory environments.

What is ISO 13485 and why is it relevant to procurement?

ISO 13485 is an international quality management system standard specifically for medical device manufacturers. Certification requires demonstrated process control, risk management, design controls, traceability, and continual improvement. For procurement officers, ISO 13485 certification provides assurance that the manufacturer operates under a recognized quality framework. ASC operates under ISO 13485 quality systems.

How can a procurement officer verify a device's 510(k) clearance?

The FDA maintains a public 510(k) database (the FDA 510(k) Premarket Notification database) that can be searched by K-number, product code, manufacturer, or device name. Each clearance record includes the clearance letter, the intended use statement, the predicate device identification, and the date of clearance. Procurement officers should request the K-number from the bidder and verify the clearance independently in the FDA database. Vendors who decline to provide the K-number should not be considered for clinical or workplace procurement.

What is an Investigational Device Exemption and when is it appropriate?

An Investigational Device Exemption under 21 CFR Part 812 authorizes the use of an unapproved or uncleared medical device in a clinical investigation to gather safety and effectiveness data in support of a future marketing application. IDE use requires an Institutional Review Board-approved protocol, informed consent, investigator qualification, and ongoing FDA reporting. IDE devices are not appropriate for routine clinical or workplace procurement and should not be specified for those applications.

What liability exposure does an institution face from using non-cleared devices?

Using non-cleared devices for clinical or workplace decision-making exposes the institution to multiple categories of liability. Regulatory exposure includes potential FDA enforcement and reimbursement disallowance. Civil liability exposure includes claims by employees, patients, or other parties affected by decisions made on the basis of non-cleared device results. Litigation defense exposure increases substantially because the institution must defend its choice to use a non-cleared device against established alternatives. The exposure is avoidable through procurement specification.

How does ASC support FDA 510(k) procurement specifically?

American Screening Corp. markets FDA 510(k) Cleared drug testing devices with specific intended use statements aligned with workplace screening, clinical point-of-care, and laboratory applications. Devices are CLIA-Waived where appropriate, manufactured under ISO 13485 quality systems, supplied with lot-coded traceability and QR-linked certificates of analysis, dispatched same-day from Shreveport, Louisiana before 2 p.m. Central, available with NET-30 terms for qualified institutional purchasers, and priced at 10, 50, 100, 500, and 1,000-plus volume tiers. The Hospitals industry program, the certificate of analysis program, and the CLIA-Waived FDA cleared cups collection consolidate the regulatory and procurement documentation.

Key takeaways

• FDA 510(k) Cleared, Investigational, and Research Use Only are statutorily distinct regulatory categories with different intended uses and procurement implications.
• For clinical and workplace drug testing, the procurement specification must require 510(k) clearance for the relevant intended use; RUO and IUO products are not acceptable substitutes.
• The intended use statement in the 510(k) clearance letter is the operative legal language; procurement officers should verify the clearance directly in the FDA database.
• CLIA classification determines the testing environment in which the device may be used and should align with the procuring institution's CLIA certification.
• ISO 13485 quality system certification provides an additional procurement assurance and is the standard for medical device manufacturers.
• ASC's FDA 510(k) Cleared, CLIA-Waived, ISO 13485 supply line with Shreveport same-day dispatch and NET-30 terms supports clinical and workplace procurement at every scale.

Related reading

• Chain of Custody for Court-Defensible Drug Testing: A Step-by-Step Procurement Checklist
• Drug Testing Procurement RFP Template: Sample Specifications for Federal Buyers
• Treatment Center Drug Screening Programs: Volume Pricing and Subscribe-and-Save Math

Bottom CTA

Hospital quality assurance directors, regulatory affairs officers, and clinical procurement leads responsible for in vitro diagnostic drug testing procurement should anchor every specification to FDA 510(k) clearance for the relevant intended use and should require independent verification through the FDA database. To receive ASC's 510(k) clearance documentation, intended use statements, CLIA classification confirmations, ISO 13485 certification, lot-coded device traceability records, and QR-linked certificates of analysis for procurement diligence, request documentation through the certificate of analysis program. Same-day dispatch from Shreveport, Louisiana applies to orders placed before 2 p.m. Central, NET-30 terms are available for qualified institutional purchasers, and the Hospitals industry program consolidates the clinical offering into a single procurement package.

---

Author note: Dr. Patrick Vandersteel, PhD, is Director of Regulatory Affairs at American Screening Corp. He holds a doctorate in regulatory science and has spent twenty years in medical device regulatory affairs across in vitro diagnostics, point-of-care testing, and clinical chemistry product lines. He has prepared and supported 510(k) submissions, IDE applications, and quality system inspections across multiple FDA review divisions. ASC is an FDA 510(k) Cleared, CLIA-Waived, ISO 13485 supplier headquartered in Shreveport, Louisiana, with same-day dispatch before 2 p.m. Central and NET-30 terms available for qualified institutional purchasers.